Drug intelligence / Profile preview

phenoxybenzamine + phentolamine

Development stage: Unknown
Lead developer: Wellcome
Modality: Small Molecules
Administration: Oral, Intravenous, Subcutaneous

Overview

A combination of two non-selective alpha-adrenergic antagonists. Phenoxybenzamine is a long-acting, irreversible alpha blocker with a half-life of 24 hours, while phentolamine is a shorter-acting, reversible alpha blocker with a half-life of 1 hour. Both medications are used in the management of pheochromocytoma but with different clinical applications due to their pharmacokinetic differences.

Targets

ADRA1A (α1A)ADRA2A (α2A)

Beyond the preview

Go deeper on phenoxybenzamine + phentolamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on phenoxybenzamine + phentolamine.

Explore the full profile